Papapetropoulos Spyros — SEC Form 4 filings

SEC reporting owner CIK 1832694. 5 Form 4 filings on record with FilingPulse; latest filed 2025-09-02.

Transaction summary — filings shown

Covers all 5 filings on record, filed 2024-06-07 to 2025-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Neuphoria Therapeutics Inc. (NEUP)President and CEO, Director33
Lipocine Inc. (LPCN)Director22

Form 4 filings — Papapetropoulos Spyros

FiledFormIssuerReported transactionsSource
2025-09-024Neuphoria Therapeutics Inc. (NEUP)Grant/award (A): 34,559 (derivative) @ $8.27EDGAR
2025-06-054Lipocine Inc. (LPCN)Grant/award (A): 1,764 (derivative) @ $3.20EDGAR
2025-05-194/ANeuphoria Therapeutics Inc. (NEUP)Grant/award (A): 27,000 (derivative) @ $5.16EDGAR
2025-04-184Neuphoria Therapeutics Inc. (NEUP)Grant/award (A): 270,000 (derivative) @ $5.16EDGAR
2024-06-074Lipocine Inc. (LPCN)Grant/award (A): 1,764 (derivative) @ $7.05EDGAR

FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1832694 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →